Background
Brian Rifkin
Dialyze Less, Recover More? AKI’s Chance to Get ...

This week, we will discuss whether less is more when it comes to discontinuing dialysis in patients with AKI and a chance to recover.

Dialyze Less, Recover More? AKI’s Chance to Get LIBERATE-D
Background
Brian Rifkin
Fish Oil in Dialysis: A Big Catch or an Empty ...

Holy Mackerel! This week we will discuss fish oil use in maintenance hemodialysis patients. Could this be the one thing that bends the curve on CV mortality, or is it just a red herring?

Fish Oil in Dialysis: A Big Catch or an Empty Net
Background
Brian Rifkin
Attacking the Origin of IgAN: ORIGIN3 and ...

This week, we will discuss the phase 3 ORIGIN3 trial of atacicept, an APRIL/BAFF inhibitor for use in IgAN.

Attacking the Origin of IgAN: ORIGIN3 and Atacicept
news
swapnil hiremath
Kidney Week in Houston: Day 3

Day 3 of Kidney Week. Sibeprenlimab and Balcinrenone on NEJM and Lancet, plus a couple of other non-kidneywk studies.

Kidney Week in Houston: Day 3
Background, news
swapnil hiremath
Kidney Week in Houston: Day 2

in this edition: Fish Oil, GBD, Flozination meta-analysis, CHW intervention in Hispanic/Latino patients, and much more

Kidney Week in Houston: Day 2

Can Canaglifozin Communicate Consistency with CANVAS?

Can Canaglifozin Communicate Consistency with CANVAS?

Were the EMPA-REG Renal results chance, or is this a class effect? Let's take a deep dive into CANVAS, published in the NEJM recently, which examined the cardiovascular safety of canaglifozin in type 2 diabetes. 

The DESCARTES chat wrap up

Another fantastic chat. (and while you are at it - check out the two patient perspectives!) 

American Chat Transcript
EU Chat Transcripts

The AKI Pregnancy Chat Wrap up

Great to have First Author, Jessica Tangren join us!

Anna Burgner made her debut hosting the American Chat, and Ben did a great job as always with the EU version

American Chat Transcript
EU Chat Transcript